BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Targets Advanced Breast Cancer with Proprietary Immunotherapy
Developing Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer Initiated FDA-approved phase IIa combination study of BRIA-IMT with Merck & Co. Inc.’s KEYTRUDA Impressive results in two proof-of-concept clinical trials reveal rapid response rate, repeated response following retreatment and excellent safety profile Cancer immunotherapy market is anticipated to grow to $145 billion by 2022, at a CAGR of 14 percent BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical-stage biotechnology company that’s currently focused on the development of targeted immunotherapy solutions for advanced breast cancer patients, has, to date, demonstrated excellent results with Bria-IMT in several clinical trials.…







